Company / SG&A Expense
INSMED Inc SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$701.2M
FY2025
5-year range
$234.3M / $701.2M
FY2021-FY2025
Trend
+52.1%
vs FY2024
Sector context
#28 of 213
Health Care
What the data says
INSMED Inc's sg&a expense of $701M is higher than 87% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 5 consecutive years, from $204M in FY2020 to $701M in FY2025.
Based on SEC 10-K filings.
$701M in FY2025 with a 5-year CAGR of +28.1%. Top quartile in the Health Care sector.
Increased from $345M to $701M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +38.2%
- 5-Year CAGR
- +28.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 213This company $701.2M Sector average $722.3M
▼
-2.9% below sector average
Key checks
Key Insights
- INSMED Inc's sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +28.1%, indicating consistent growth.
- In FY2025, sg&a expense increased 52.1% year-over-year.
- Ranks #28 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.93 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $701.2M | +52.1% |
| FY2024 | $461.1M | +33.9% |
| FY2023 | $344.5M | +29.6% |
| FY2022 | $265.8M | +13.5% |
| FY2021 | $234.3M | +15.1% |
| FY2020 | $203.6M | -3.4% |
| FY2019 | $210.8M | +25.3% |
| FY2018 | $168.2M | +112.5% |
| FY2017 | $79.2M | +56.2% |
| FY2016 | $50.7M | +17.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026